Advertisement

Topics

Janssen/AbbVie drug approved in graft-versus-host disease

09:08 EDT 7 Aug 2017 | pharmaphorum

Janssen/AbbVie’s Imbruvica has gained its first use outside of blood cancer, after the FDA approved it for chronic graft-versus-host disease (cGVHD). The decision further vindicates AbbVie’s $21 billion takeover of Pharmacyclics back in 2015, ...

Original Article: Janssen/AbbVie drug approved in graft-versus-host disease

NEXT ARTICLE

More From BioPortfolio on "Janssen/AbbVie drug approved in graft-versus-host disease"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...